News
Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...
TipRanks on MSN16h
EyePoint Pharmaceuticals Completes Promising Study on EYP-1901 for Diabetic Retinopathy
This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...
British number one blind golfer Billy McAllister recalls his journey in the sport after completely losing his eyesight in ...
Macular edema (ME), a leading cause of central vision loss, is often treated with anti-vascular endothelial growth factor ...
A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...
GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.
Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...
The Sultanate of Oman is the third country worldwide to implement this project, confirming its commitment to technological ...
For the first time in Ghana’s history, the country officially joins the global eye care community in commemorating World ...
A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...
Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...
Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results